MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, appointed Trine Ahlgreen as Chief Executive Officer.

The transition to new leadership reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion. Ahlgreen will help expand its commercial asset, Wynzora Cream, and maximize the commercial potential of its formulation and drug delivery system, PAD Technology.

Jesper J. Lange has served as the company’s CEO since its inception. Under Lange’s leadership, MC2 Therapeutics developed Wynzora Cream, formed alliances with key partners on four continents, and established commercial manufacturing with three CMOs.

Ahlgreen has an extensive background spanning commercial leadership of global, regional, and local pharmaceutical product launches. She has led several successful cross-functional teams and business development across Europe, the US, and Japan. 

Ahlgreen played key roles in several high-impact product launches at Novo Nordisk, including the launches of Ozempic, Rybelsus, and the global cardiovascular indication launch for GLP-1. 

Most recently, at Swiss biotech Micreos Pharmaceuticals AG, Trine built the commercial and business development infrastructure focused on dermatology, forging valuable strategic partnerships across pharma and OTC.

“MC2 Therapeutics has developed world-class innovation in topical therapies with a unique commitment to patient adherence and uncompromised efficacy”, said Ahlgreen. “I’m honored to lead the next phase of the company’s growth, focused on realizing the full global commercial potential of Wynzora Cream for plaque psoriasis, while exploring new opportunities through our proprietary PAD Technology formulation platform with selected partners.”